More Clinical Articles

Access and Evidence

Real World Data: Promises and Challenges

Zuzanna Fimińska, (Feb 18, 2014)

Big data, big promises, but getting the complete picture needs multiple sources of information. Real World Data (RWD), randomized clinical trials (RCTs), and small-scale, focus-group-based surveys are not members of opposite teams, but pieces of the same puzzle.
Commercial

Using Electronic Patient-Reported Outcomes (ePRO) for the First Time: Lessons Learned

Darja Turner, (Dec 19, 2013)

The importance of patient-reported outcomes (PROs) is evidenced by their increased use in clinical trials and in drug and device label claims. Here Darja Turner shares her experiences using an electronic PRO tool for the first time.
Clinical

The Pharma/University Partnership is Vital to Drug Discovery

Zuzanna Fimińska, (Aug 19, 2013)

Most major academic institutions around the world now have an alliance with the industry. By reaching out to communities rich in scientific talent and creativity, drug manufacturers hope to identify novel molecules and new uses for the old ones.
Commercial

A Healthcare Revolution: Virtual Innovation at Full Speed

Louise Kelly, (Aug 6, 2013)

A number of players are working on combining patient health information with their own innovative virtual models, fine-tuning relevant the data for effective use. Where clinical trials may not be possible – or effective – these tools could become a viable alternative.
Clinical

Bayer Enters $540 Million Cancer Deal With Compugen

Lucy Brake, (Aug 6, 2013)

Bayer and Compugen have announced this week that they have signed a cancer immunotherapy deal which has the potential to be worth over US $540 million to the Israeli biotechnology company.
Clinical

Drug Firms Praise New “Breakthrough” FDA Pathway

Ben Steele, (Jul 26, 2013)

Johnson & Johnson and Vertex Pharmaceuticals, two companies whose drugs have received “breakthrough therapy” designation, have spoken out in support of the FDA’s new breakthrough program, which could shave years off of the approval process.
Access and Evidence

UPDATED Exclusive: The Devil is in the Detail – How The Guardian's Bias Towards One Leaked Memo Proves Greater Transparency is Needed From All

Craig Sharp, (Jul 26, 2013)

The ongoing battle for clinical trial transparency took an unexpected turn this past Sunday, 21st July, when the Guardian ran a story featuring details of a leaked memo, apparently containing a plan to conceal “secret documents on drugs trials” from the public and concerned medical practitioners.
Access and Evidence

Exclusive: Richard Bergström Explains Transatlantic Joint Principles for Clinical Data Sharing

Craig Sharp, (Jul 26, 2013)

This week the European Federation of Pharmaceutical Industries and Associations (EFPIA) and Pharmaceutical Research and Manufacturers of America (PhRMA) released a joint position paper for responsible clinical trial data sharing to benefit patients.
Clinical

The Pharma Potential to Tap into Biobanks

Lina Genovesi, (Jul 25, 2013)

George Dagher, PhD, coordinator of the French infrastructure for biobanks and leader of funding and financing WP, Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) shares some thoughts with Lina Genovesi on the opportunities of biobanks for pharma.
Clinical

Pay-for-Delay Deals could be Essential for More Generics and Cheaper Medicines

Anonymous, (Jul 24, 2013)

Limiting pay-for-delay deals will reduce pharmaceutical investment in generics and increase the cost of medicines for patients, states global economic consulting firm.

Pages